Sarah Cannon Research Institute shared a post on LinkedIn:
“Meredith Sellers Pelster shares her insights on the meaningful results of the Breakwater study for colorectal patients with BRAF V600E Mutation with Endpoints News.”
Quoting Meredith Sellers Pelster‘s post:
“Honored to share my thoughts with Endpoints on the meaningful results of the Breakwater study for colorectal cancer patients. The patient population with BRAF V600E mutation has historically had a poor prognosis, and we are excited about the impact this advancement can have on patients who need more treatment options.”